CART-19 Cells For R/R B-ALL

Fujian Medical University20 enrolled

Overview

There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Relapsed/Refractory B-cell ALL

Interventions

CART-19 cellsBIOLOGICAL

CART-19 cells treat

Eligibility

Sex: ALLMin age: 1 YearMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed written informed consent * Aged between 1-60 years * Patients with relapsed/refractory B-cell ALL * Cardiac: Left ventricular ejection fraction ≥ 50% * Adequate renal and hepatic function * Performance status: Karnofsky ≥ 70% Exclusion Criteria: * Pregnant or lactating females. * Any co-morbidity precluding the administration of CART-19 cells.

Locations (1)

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

RECRUITING

Outcomes

Primary Outcomes

Leukemia free survival

Time frame: 1 year

Secondary Outcomes

Adverse events that are related to treatment

Time frame: 1 year

Central Contacts

Jianda Hu, Prof.M.D.Ph.D

CONTACT

86-13959169016 drjiandahu@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.